| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11154-017-9416-1 |
| P698 | PubMed publication ID | 28258533 |
| P50 | author | Vishnu Garla | Q87004652 |
| P2093 | author name string | Lillian F Lien | |
| Licy Yanes-Cardozo | |||
| P2860 | cites work | Economic costs of diabetes in the U.S. in 2012 | Q22241287 |
| Inflammation and insulin resistance | Q22241893 | ||
| Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making | Q26992979 | ||
| Updates on the management of diabetes in dialysis patients | Q27024782 | ||
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
| Insulin degradation: progress and potential | Q28287093 | ||
| Renal gluconeogenesis: its importance in human glucose homeostasis | Q32050169 | ||
| Management of diabetes mellitus in patients with chronic kidney disease | Q33792375 | ||
| Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence | Q33854022 | ||
| Hypoglycemia in type 1 diabetes mellitus | Q34072593 | ||
| Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications | Q34120717 | ||
| Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes | Q34429278 | ||
| Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes | Q34457919 | ||
| Role of parathyroid hormone in the glucose intolerance of chronic renal failure | Q34538093 | ||
| Metabolic acidosis-induced insulin resistance and cardiovascular risk | Q35163137 | ||
| Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences | Q35569527 | ||
| Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes | Q35721420 | ||
| Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease | Q35887931 | ||
| Comparison of the Effects of Pioglitazone versus Placebo when Given in Addition to Standard Insulin Treatment in Patients with Type 2 Diabetes Mellitus Requiring Hemodialysis: Results from the PIOren Study | Q36058654 | ||
| A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency | Q36249553 | ||
| Hemoglobin A(1c) levels and mortality in the diabetic hemodialysis population: findings from the Dialysis Outcomes and Practice Patterns Study (DOPPS). | Q36426859 | ||
| Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study | Q36560252 | ||
| Defective counterregulation and hypoglycemia unawareness in diabetes: mechanisms and emerging treatments | Q36597980 | ||
| Evidence for interindividual heterogeneity in the glucose gradient across the human red blood cell membrane and its relationship to hemoglobin glycation | Q36842619 | ||
| Skeletal consequences of thiazolidinedione therapy | Q36954391 | ||
| Insulin requirements in patients with diabetes and declining kidney function: differences between insulin analogues and human insulin? | Q37127547 | ||
| Rosiglitazone is associated with mortality in chronic hemodialysis patients. | Q37181975 | ||
| Effects of cabergoline on blood glucose levels in type 2 diabetic patients: A double-blind controlled clinical trial. | Q37328780 | ||
| A comparison of two insulin infusion protocols in the medical intensive care unit by continuous glucose monitoring. | Q37430563 | ||
| Insulin degludec: pharmacokinetics in patients with renal impairment | Q37506526 | ||
| Elevated 1-hour plasma glucose levels are associated with dysglycemia, impaired beta-cell function, and insulin sensitivity: a pilot study from a real world health care setting | Q37656220 | ||
| Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice | Q37837923 | ||
| Glucose handling by the kidney | Q37848041 | ||
| Glycemic control in diabetic dialysis patients and the burnt-out diabetes phenomenon | Q38013676 | ||
| Diabetes management in the kidney patient | Q38071788 | ||
| Glycemic management in ESRD and earlier stages of CKD. | Q38181703 | ||
| KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. | Q38197453 | ||
| Hypoglycemia, chronic kidney disease, and diabetes mellitus | Q38259151 | ||
| Transitioning safely from intravenous to subcutaneous insulin | Q38378748 | ||
| Haemodialysis-induced hypoglycaemia and glycaemic disarrays | Q38409082 | ||
| Evaluation and management of diabetic and non-diabetic hypoglycemia in end-stage renal disease | Q38543658 | ||
| Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents | Q38585136 | ||
| Reasons why patients referred to diabetes education programmes choose not to attend: a systematic review | Q38782459 | ||
| KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update | Q39535980 | ||
| Octreotide: an antidote for sulfonylurea-induced hypoglycemia | Q39543312 | ||
| SGLT2 Inhibitors and the Diabetic Kidney | Q39578117 | ||
| One-hour post-load plasma glucose level during the OGTT predicts dysglycemia: Observations from the 24year follow-up of the Israel Study of Glucose Intolerance, Obesity and Hypertension | Q40594386 | ||
| CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. | Q41000321 | ||
| The Management of Diabetes Mellitus in Patients with Chronic Kidney Disease: A Population-Based Study in Southern Italy. | Q41030612 | ||
| Hypoglycemia in the treatment of hyperkalemia with insulin in patients with end-stage renal disease | Q41809881 | ||
| Glycated albumin, not hemoglobin A1c, predicts cardiovascular hospitalization and length of stay in diabetic patients on dialysis | Q42286738 | ||
| Severe hyperkalaemia resulting from octreotide use in a haemodialysis patient | Q42977042 | ||
| Hemoglobin A(1c) and fructosamine for assessing glycemic control in diabetic patients with CKD stages 3 and 4. | Q43142843 | ||
| Comparison of glycated albumin and hemoglobin A1c concentrations in diabetic subjects on peritoneal and hemodialysis | Q43199808 | ||
| Management of diabetes in dialysis patients | Q43231977 | ||
| Effect of exogenous intermittent recombinant human PTH 1-34 administration and chronic endogenous parathyroid hormone excess on glucose homeostasis and insulin sensitivity. | Q43602971 | ||
| Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients | Q43603797 | ||
| Renal substrate exchange and gluconeogenesis in normal postabsorptive humans | Q43852619 | ||
| Abnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in type 2 diabetes | Q45013706 | ||
| Red blood cell survival in chronic renal failure | Q45071574 | ||
| The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis | Q45877987 | ||
| Sequence of cellular events in pancreatic islets leading to impaired insulin secretion in chronic kidney disease | Q46067186 | ||
| Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency | Q46563222 | ||
| Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis | Q46743392 | ||
| A1C and survival in maintenance hemodialysis patients | Q46840312 | ||
| Na(+) -glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity. | Q46930511 | ||
| Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes | Q48211230 | ||
| Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society | Q48260106 | ||
| Glycated albumin is superior to glycated hemoglobin for glycemic control assessment at an early stage of diabetes treatment: A multicenter, prospective study. | Q51280783 | ||
| Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study. | Q51318574 | ||
| Prolactin Promotes Adipose Tissue Fitness and Insulin Sensitivity in Obese Males. | Q51349277 | ||
| Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. | Q51367101 | ||
| Icodextrine and insulin resistance in continuous ambulatory peritoneal dialysis patients. | Q51471397 | ||
| Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. | Q51487703 | ||
| Renal glucose production compensates for the liver during the anhepatic phase of liver transplantation. | Q51555513 | ||
| The influence of hyperparathyroidism on glucose metabolism in uremia. | Q54455668 | ||
| Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration | Q57412996 | ||
| P433 | issue | 1 | |
| P921 | main subject | hyperglycemia | Q271993 |
| P304 | page(s) | 5-19 | |
| P577 | publication date | 2017-03-01 | |
| P1433 | published in | Reviews in Endocrine and Metabolic Disorders | Q15766899 |
| P1476 | title | Current therapeutic approaches in the management of hyperglycemia in chronic renal disease | |
| P478 | volume | 18 |
| Q47114123 | Effects of Intensive Control of Glycemia on Clinical Kidney Outcomes in Type 2 Diabetes Patients Compared with Standard Control: A Meta-Analysis. |
| Q87657435 | Nephroendocrinology: When endocrinology meets nephrology |
| Q92432388 | PROTECTIVE EFFECT OF INSULIN TREATMENT ON EARLY RENAL CHANGES IN STREPTOZOTOCIN-INDUCED DIABETIC RATS |
Search more.